Combination therapy for advanced prostate cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination treatment for men with advanced prostate cancer that has spread to the bones and stopped responding to standard hormone therapy or chemotherapy. The treatment combines an experimental drug (LC-K76) with a type of immunotherapy (anti-PD-1) that helps your immune system fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 85 years old.
- Your cancer is a type called prostate adenocarcinoma (not small cell).
- Your cancer has spread and is still growing despite hormone therapy (like abiraterone or enzalutamide) or chemotherapy (like docetaxel).
- You have bone metastases seen on a PSMA-PET-CT or bone scan.
- You have never been treated with an immune checkpoint inhibitor (like Keytruda or Opdivo).
- You are willing to have two biopsies (tissue samples) of your tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
This trial tests a combination of a radioactive drug that seeks out prostate cancer cells (Lutetium-177) with an immunotherapy (pembrolizumab). It is for men whose castration-resistant prostate cancer has spread and is no longer controlled by current hormone treatments.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial combines three treatments—a targeted radioactive therapy (177Lu-PSMA), a PARP inhibitor (olaparib), and an immunotherapy (pembrolizumab)—to see if they work better together against advanced prostate cancer that has stopped responding to hormone therapy. You may join if your cancer shows strong PSMA on scans and you have already tried certain hormone blockers but your cancer continued to grow.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.